Osteoporosis patients treatment satisfaction questionnaires (OPSAT-Q) in postmenopausal women treated with once-monthly bisphosphonates and once-weekly bisphosphonates

kidney function and is not associated with an increase in adverse events among patients with impaired kidney function. Disclosure of Interest: S. Jamal: None declared, O. Ljunggren: None declared, C. Stehman-Breen: None declared, S. Cummings: None declared, M. McClung: None declared, S. Goemaere: None declared, P. Ebeling: None declared, E. Franek: None declared, Y.-C. Yang Shareholder of Amgen Inc, Employee of Amgen Inc, O. Egbuna Shareholder of Amgen Inc, Employee of Amgen Inc, P. Miller: None declared